Nektar Therapeutics (NKTR) is a Healthcare stock trading at $74.00 (as of 2026-08-21), with a market capitalization of $2.53B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics develops biopharmaceutical medicines for unmet medical needs, with Bempegaldesleukin in multiple clinical trials (including phase 3 in metastatic melanoma, renal cell carcinoma, and other cancers), and it earns money mainly through licensing, collaboration arrangements, and non-cash royalty revenue tied to future royalties.
As a clinical-stage biopharma, the company’s economic outcomes depend on whether its trial-stage assets, such as Bempegaldesleukin, progress to results that support future partnering, licensing, or royalty value, since current recognized revenue is minimal and losses dominate.
| Non-cash Future Royalties | $0.0B |
| License Collab Other | $0.0B |
Business quality (Weak): The provided quarter data shows essentially zero revenue and no gross margin, so the company’s near-term fundamentals look clinical-stage and loss-driven rather than commercially driven.
| Price | $74.00 |
| Market Cap | $2.53B |
| Price / Book | 2.80 |
| Price / Sales | 46.28 |
| FCF Yield | -9.3% |
| Revenue (TTM) | $55.23M |
| Net Margin | -297.1% |
| Revenue Growth (YoY) | -9.3% |
| EPS Growth (YoY) | -58.3% |
| FCF Growth (YoY) | 65.7% |
| Altman Z-Score | -12.63 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | FMR LLC ($309.61M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Howard W. Robin |
| Employees | 61 |
| Country | US |
| IPO Date | 1994-05-03 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.